Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.43 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 9/20 | 0.42 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.42 |
| ▸ | PRKACA | P17612 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1582038 | 0.82 | BCL2L1 (0.40) | S100A4KMT2AMEN1NPC1RAB9A | |
| SCHEMBL7216241 | 0.78 | KMT2A (0.53) | KMT2AMEN1NPC1RAB9AABCG2 | |
| SCHEMBL27844725 | 0.75 | ALDH1A1 (0.59) | CRHBPCRHR2KMT2AMEN1NPC1 | |
| SCHEMBL8211417 | 0.74 | MEN1 (0.62) | KMT2AMEN1NPC1RAB9APAX8 | |
| SCHEMBL11632084 | 0.74 | DHODH (0.48) | S100A4CRHBPCRHR2KMT2AMEN1 | |
| SCHEMBL22604036 | 0.73 | MAPK1 (0.62) | KMT2AMEN1NPC1RAB9APOLB | |
| SCHEMBL28579892 | 0.73 | S100A4 (0.50) | S100A4KMT2AMEN1RAB9APOLB | |
| SCHEMBL596720 | 0.73 | MEN1 (0.48) | KMT2AMEN1POLBCASP6 | |
| SCHEMBL596719 | 0.73 | MEN1 (0.48) | KMT2AMEN1POLBCASP6 | |
| SCHEMBL27982550 | 0.71 | ABCC8 (0.63) | S100A4CRHBPCRHR2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0738717-A1 | Certain substituted pyrimidines as intermediates for production of cycloalkyl and azacycloalkyl pyrrolopyrimidines | NEUROGEN CORPORATION (US) | 1996-10-23 | — | — | EP | claimed |
| US-9353115-B2 | Immune system modulators | JANUS BIOTHERAPEUTICS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353115-B2 | Immune system modulators | JANUS BIOTHERAPEUTICS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353115-B2 | Immune system modulators | JANUS BIOTHERAPEUTICS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2713737-B1 | NOVEL IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS INC (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-2713737-B1 | NOVEL IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20140107115-A1 | NOVEL IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107115-A1 | NOVEL IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107115-A1 | NOVEL IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| WO-2012167053-A1 | NOVEL IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| US-5463054-A | Diagnosis and treatment of anxiety, sleep, seizure disorders, overdose with benzodiazepine drugs, enhancement of memory | NEUROGEN CORPORATION (US) | 1995-10-31 | — | — | US | disclosed |
| WO-1994025463-A1 | CERTAIN ARYL FUSED PYRROLOPYRIMIDINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1994-11-10 | — | — | WO | disclosed |
| US-5326868-A | Treatment of sleep disorders, anxiety, seizures, memory | NEUROGEN CORPORATION (US) | 1994-07-05 | — | — | US | disclosed |
| CN-1076929-A | Some cycloalkyl and azacycloalkyl pyrrolopyrimidines; The γ-An Jidingsuan brain receptor ligands that one class is new | NEUROGEN CORP (US) | 1993-10-06 | — | — | CN | disclosed |
| EP-0552237-A1 | CERTAIN CYCLOALKYL AND AZACYCLOALKYL PYRROLOPYRIMIDINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1993-07-28 | — | — | EP | disclosed |
| US-5216159-A | Preferential antagonists, agonists or inverse agonists for gamma-aminobutyric acid binding sites; anxiolytic agents; anticonvulsants; treatment of sleep disorders | NEUROGEN CORPORATION (US) | 1993-06-01 | — | — | US | disclosed |
| WO-1992006094-A1 | CERTAIN CYCLOALKYL AND AZACYCLOALKYL PYRROLOPYRIMIDINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1992-04-16 | — | — | WO | disclosed |
| EP-0112280-B1 | 2-ARYL-4,6-DIHALOGEN PYRIMIDINES AS ANTIDOTES FOR PROTECTING CULTIVATED PLANTS BEFORE PHYTOTOXIC DAMAGE CAUSED BY A HERBICIDE | CIBA-GEIGY AG (CH) | 1990-08-29 | — | — | EP | disclosed |
| US-4648896-A | PLANT SAFENING AGENTS | CIBA-GEIGY CORPORATION (US) | 1987-03-10 | — | — | US | disclosed |
| EP-0112280-A2 | 2-Aryl-4,6-dihalogen pyrimidines as antidotes for protecting cultivated plants before phytotoxic damage caused by a herbicide | CIBA-GEIGY AG (CH) | 1984-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107115-A1 | NOVEL IMMUNE SYSTEM MODULATORS | HLA-DRB1, CD47, MYD88 | S100A4 533/4885CRHBP 3221/4885CRHR2 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.